Age-Related Macular Degeneration (AMD) Topical Map: SEO Clusters
Use this Age-Related Macular Degeneration (AMD) Guide topical map to cover what is age-related macular degeneration with topic clusters, pillar pages, article ideas, content briefs, AI prompts, and publishing order.
Built for SEOs, agencies, bloggers, and content teams that need a practical content plan for Google rankings, AI Overview eligibility, and LLM citation.
1. Basics: What AMD Is, Who Gets It, and Early Signs
Defines AMD, explains the macula's role, describes dry vs wet forms and stages, and outlines symptoms and risk factors so readers can recognize disease and understand who is most at risk.
What Is Age-Related Macular Degeneration? Types, Stages, Symptoms, and Risk Factors
A definitive primer on AMD that explains retinal anatomy, distinguishes dry (atrophic) and wet (neovascular) AMD, defines early/intermediate/advanced stages, lists signs and symptoms, and reviews proven risk factors (age, smoking, genetics, cardiovascular disease). Readers gain a clear framework for self-monitoring, understanding prognosis, and knowing when to seek specialist care.
Age-Related Macular Degeneration Symptoms: How to Spot Early Signs
Lists specific visual changes (blurred central vision, metamorphopsia, scotomas, reduced contrast) and practical self-checks (Amsler grid, reading tests) so readers can identify early AMD and know when to get evaluated.
Dry AMD vs Wet AMD: Key Differences, Symptoms, and Prognosis
Explains pathophysiology, clinical presentation, speed of vision loss, and typical outcomes for dry and wet AMD to help readers understand their diagnosis and likely course.
AMD Risk Factors: Age, Smoking, Genetics, and Modifiable Risks
Examines established and emerging risk factors, quantifies relative risks where possible, and highlights modifiable behaviors that reduce progression risk.
Stages of AMD Explained: From Drusen to Geographic Atrophy
Defines clinical stage criteria (drusen size/number, pigmentary changes, geographic atrophy, neovascularization) and explains implications for monitoring and treatment.
When to See an Eye Doctor: Urgent Signs and Routine Monitoring for AMD
Gives clear guidance on urgent symptoms (sudden distortion or central dark spot), recommended follow-up intervals, and screening recommendations for at-risk populations.
2. Diagnosis & Imaging: How AMD Is Detected and Monitored
Covers clinical exams, home monitoring tools, and advanced imaging (OCT, fluorescein angiography, fundus photography) so patients and clinicians can interpret findings and choose the correct follow-up or treatment path.
How Macular Degeneration Is Diagnosed: Exams, Amsler Grid, OCT, and Angiography
Comprehensive explanation of diagnostic workflow: primary eye exam signs, use of Amsler grid and home-monitoring, and detailed guidance on OCT, fundus photography, fluorescein and indocyanine green angiography. Readers learn what each test shows, how often to repeat tests, and how results guide treatment choices.
OCT for AMD: What OCT Images Show and How to Read a Report
Explains OCT technology, common patterns (subretinal fluid, intraretinal cysts, pigment epithelial detachments, drusen), and practical tips to interpret OCT reports and images.
Fluorescein Angiography and Indocyanine Green in AMD: When They're Needed
Describes indications, procedure, image patterns that diagnose neovascular membranes, and risks/contraindications for angiography.
How to Use the Amsler Grid and Smartphone Apps for Home Monitoring
Step-by-step instructions for Amsler grid use, an overview of validated home-monitoring apps (ForeseeHome, others), and evidence on sensitivity for detecting conversion to wet AMD.
When to Refer to a Retinal Specialist: Red Flags and Timing
Defines urgent referral criteria, routine referral timing for intermediate/advanced AMD, and what information to provide to the specialist.
Genetic Testing for AMD: What It Shows and When It's Useful
Reviews common AMD-associated genes (CFH, ARMS2), clinical utility, limitations, and counseling considerations.
3. Treatment & Medical Management
Detailed, evidence-based guidance on current standard-of-care treatments (anti-VEGF injections, photodynamic therapy), supplements (AREDS/AREDS2), management strategies for dry AMD and geographic atrophy, and practical considerations around procedures and follow-up.
Treatments for Age-Related Macular Degeneration: Anti-VEGF, Supplements, Procedures, and Management Plans
Authoritative review of therapeutic options for wet and dry AMD: detailed anti-VEGF drug profiles and treatment regimens, assessment of supplements (AREDS/AREDS2), description of photodynamic and laser therapies, management of geographic atrophy, and guidance on treatment decisions, complications, and monitoring schedules.
Anti-VEGF Therapy for AMD: Lucentis, Eylea, Avastin — Comparisons and Practical Guide
In-depth comparison of ranibizumab, aflibercept, and bevacizumab: mechanism, trial data, dosing regimens (monthly, PRN, treat-and-extend), expected outcomes, risks, and real-world considerations.
AREDS and AREDS2 Supplements: Evidence, Formulations, and Who Should Take Them
Summarizes AREDS/AREDS2 trial evidence, details recommended formulations and dosing, contraindications (e.g., smoking and beta-carotene), and guidance for clinicians and patients.
Managing Geographic Atrophy (Advanced Dry AMD): Current Care and Emerging Options
Explains how geographic atrophy is monitored, supportive care and low-vision options, what treatments are currently available or close to approval, and how to counsel patients on prognosis.
Photodynamic Therapy, Laser, and Other Procedural Options for AMD
Reviews verteporfin PDT, older thermal laser uses, current niches for these procedures, and why anti-VEGF replaced many prior treatments.
Managing Complications and Injection-Related Risks: Endophthalmitis, IOP Spikes, and Systemic Concerns
Describes potential local and systemic risks of intraocular injections, prevention protocols, signs of complications, and emergency actions.
Cost, Insurance, and Access to AMD Treatments: Navigating Coverage (US Focus)
Explains typical costs, Medicare/insurance coverage nuances, biosimilars and off-label bevacizumab use, patient assistance programs, and cost-reduction strategies.
4. Prevention & Lifestyle: Reduce Risk and Slow Progression
Actionable guidance on lifestyle changes, nutrition, supplements, and modifiable health factors that reduce AMD risk and may slow progression—important for patients and caregivers.
Preventing Progression of AMD: Nutrition, Supplements, Smoking Cessation, and Lifestyle Strategies
A practical guide synthesizing the best evidence on modifiable risk reduction: smoking cessation, dietary patterns (lutein/zeaxanthin, omega-3s, leafy greens), exercise and cardiovascular risk control, safe supplement use (AREDS guidance), and routine monitoring to catch conversion early.
Diet and Nutrition for AMD: Foods, Nutrients, and Meal Plans
Evidence-backed food guidance emphasizing leafy greens, lutein, zeaxanthin, omega-3 sources, and practical meal planning tips to support retinal health.
Supplements Guide for AMD: Which Formulation, Dosage, and Safety Issues to Know
Explains AREDS/AREDS2 formulations, alternative products, interactions (e.g., with statins, blood thinners), and how to choose a high-quality supplement.
Smoking and AMD: How Quitting Lowers Risk and Proven Cessation Strategies
Summarizes the magnitude of smoking-related risk and practical, evidence-based methods to quit (pharmacotherapy, counseling) tailored to older adults.
Blue Light, Sunglasses, and Sunlight: What Protects Your Retina?
Separates myths from evidence regarding blue-light blocking devices, UV protection, and sunglasses recommendations.
Exercise and Cardiovascular Health for Eye Protection: Practical Recommendations
Explains links between cardiovascular risk factors and AMD progression and gives safe exercise guidance for older adults.
5. Living with AMD: Low-Vision Rehabilitation and Daily Life
Focuses on practical adaptations, low-vision devices, legal/occupational issues, mental health, and support resources so people with AMD can maximize independence and quality of life.
Living Well with Age-Related Macular Degeneration: Low-Vision Aids, Home Adaptations, and Support Services
A patient-centered resource detailing low-vision devices (optical and electronic), smartphone accessibility tools, home safety modifications, driving and legal considerations, psychological coping strategies, and where to find rehabilitation services and community support.
Best Low-Vision Devices and Apps for AMD: A Practical Buyer's Guide
Compares optical magnifiers, electronic CCTVs, wearable devices, reading aids, and top apps with pros/cons, costs, and user scenarios to help readers choose appropriate tools.
Home Safety and Daily Living Adaptations for Central Vision Loss
Practical checklist for lighting, contrast, labeling, kitchen/ bathroom safety, and simple home changes that increase independence.
Driving and Legal Considerations with AMD: How to Assess Fitness and Plan Alternatives
Explains vision standards for driving, assessment options, counseling patients on driving cessation, and mobility alternatives (transportation services, ride shares).
Mental Health and Coping with Vision Loss: Resources for Patients and Caregivers
Addresses depression/anxiety risks, counseling options, peer support groups, and caregiver burnout prevention strategies.
What to Expect from a Low-Vision Rehabilitation Clinic: Services and Outcomes
Describes evaluation components, individualized rehabilitation plans, assistive technologies training, and realistic functional goals.
6. Research & Future Therapies
Explains cutting-edge research, clinical trials, and emerging therapies (gene therapy, complement inhibitors, stem cells, sustained-delivery systems) so readers can understand future options and assess trial participation.
The Future of AMD: Gene Therapy, Complement Inhibitors, Stem Cells, and Emerging Treatments
A forward-looking, evidence-based review of promising approaches in late-stage and early clinical development: complement pathway inhibitors, gene therapies, stem cell and retinal implant strategies, sustained-delivery anti-VEGF technologies, and how to evaluate trial data and access clinical studies.
Gene Therapy for AMD: Mechanisms, Key Trials, and Patient Eligibility
Summarizes vector types, therapeutic targets, notable trials, safety considerations, and which patients might be eligible for gene therapy studies.
Complement Pathway Inhibitors and Immunomodulation: What's Promising for Geographic Atrophy
Explains the biology of complement-mediated damage, reviews leading drugs (e.g., pegcetacoplan), clinical trial outcomes, and safety/efficacy trade-offs.
Stem Cells and Retinal Implants: Current Status, Risks, and Realistic Expectations
Covers RPE cell replacement, retinal patch implants, trial results to date, and safety concerns including immune response and tumor risk.
Sustained-Delivery Anti-VEGF Systems and Novel Drug Delivery Approaches
Reviews port delivery systems, long-acting molecules, and other technologies aimed at reducing injection frequency and their clinical evidence.
How to Find and Join Clinical Trials for AMD: Resources and Practical Steps
Practical guide to ClinicalTrials.gov, institutional registries, eligibility screening, informed consent, and balancing risks/benefits when considering trials.
Recent FDA Decisions and Regulatory Updates Affecting AMD Care
Summarizes recent approvals, advisory committee decisions, label changes, and how regulatory actions affect access to new AMD treatments.
Content strategy and topical authority plan for Age-Related Macular Degeneration (AMD) Guide
The recommended SEO content strategy for Age-Related Macular Degeneration (AMD) Guide is the hub-and-spoke topical map model: one comprehensive pillar page on Age-Related Macular Degeneration (AMD) Guide, supported by 32 cluster articles each targeting a specific sub-topic. This gives Google the complete hub-and-spoke coverage it needs to rank your site as a topical authority on Age-Related Macular Degeneration (AMD) Guide.
38
Articles in plan
6
Content groups
20
High-priority articles
~6 months
Est. time to authority
Search intent coverage across Age-Related Macular Degeneration (AMD) Guide
This topical map covers the full intent mix needed to build authority, not just one article type.
Entities and concepts to cover in Age-Related Macular Degeneration (AMD) Guide
Publishing order
Start with the pillar page, then publish the 20 high-priority articles first to establish coverage around what is age-related macular degeneration faster.
Estimated time to authority: ~6 months